Avacta says AVA6103 candidate shows proof of mechanism in Phase 1
Avacta Group PLC said its AVA6103 drug candidate achieved proof of mechanism in a Phase 1 trial.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.